Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Oncology, Pharmacology +17

HLA-B*5701 Screening for Hypersensitivity to Abacavir

S. Mallal, Elizabeth J. Phillips, Giampiero Carosi et al. · New England Journal of Medicine · 2008 · 1.8K citations · Full text

Life Sciences, Dermatology, Immunology +15

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

Stephen Johnston, John Pippen, Xavier Pivot et al. · Journal of Clinical Oncology · 2009 · 1K citations · Full text

Medicine, Oncology, Pharmacology +17

Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations

Faviel F. González-Galarza, Louise Y.C. Takeshita, Eduardo José Melo dos Santos et al. · Nucleic Acids Research · 2014 · 759 citations · Full text

Life Sciences, Genetics, Immunology +17

Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan

Pei‐Jer Chen, Juei‐Jueng Lin, Chin‐Song Lu et al. · New England Journal of Medicine · 2011 · 694 citations · Full text

Life Sciences, Genetics, Pharmacology +13